CSHL Expands Lawsuit Against IP Counsel to Include Charges of Dealings with Other RNAi Clients
November 11, 2010
CSHL Expands Lawsuit Against IP Counsel to Include Charges of Dealings with Other RNAi Clients
CSHL specifically names Arrowhead Research subsidiaries Calando Pharmaceuticals and Insert Therapeutics, which were merged into one firm under the Calando name in 2008, and RXi Pharmaceuticals.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- NY Court Sends CSHL Suit Against One-Time Patent Counsel to Mass.
January 27, 2011 / Gene Silencing News - Law Firm Says New CSHL Claims Against it are Unrelated to Ongoing Suit
December 9, 2010 / Gene Silencing News - Mass. Court Dismisses CSHL Lawsuit Against Former IP Counsel
March 21, 2013 / Gene Silencing News - Sigma-Aldrich Ordered to Provide Sales Data in CSHL Suit Against Former Patent Counsel
December 13, 2012 / Gene Silencing News - As Sigma-Aldrich Fights Sales Data Subpoena, CSHL Argues that Information Will be Anonymous
December 20, 2012 / Gene Silencing News